Evidence map›Paper›PMID 42098228›Full record

ArticleScientific reports2026

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.

Simon Davenport, Bin Xie, Kevin Hamblett, Diana Hausman, Ivonne Villalobos, Hardeep P Singh, David Cobrinik, David S B Hoon, Jian-Yuan Zhou, Maria Sibug-Saber and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Simon DavenportDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Simon.Davenport@med.usc.edu.
Bin XieDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Kevin HamblettZymeworks Inc, Seattle, WA, USA.
Diana HausmanZymeworks Inc, Seattle, WA, USA.
Ivonne VillalobosDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Hardeep P SinghDepartment of Ophthalmology, Roski Eye Institute, and Norris Comprehensive Cancer Center, The Vision Center and Saban Research Institute, University of Southern California, Children's Hospital of Los Angeles, University of Southern California, Los Angeles, CA, USA.
David CobrinikDepartment of Ophthalmology, Roski Eye Institute, and Norris Comprehensive Cancer Center, The Vision Center and Saban Research Institute, University of Southern California, Children's Hospital of Los Angeles, University of Southern California, Los Angeles, CA, USA.
David S B HoonSaint John's Cancer Institute, Saint John's Health Center PHS, Santa Monica, CA, USA.
Jian-Yuan ZhouDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Maria Sibug-SaberDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Yanling MaDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Gottfried E KonecnyDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Martin HeurDepartment of Ophthalmology, Keck Medicine of USC, University of Southern California, Los Angeles, CA, USA.
Dennis J SlamonDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Michael F PressDepartment of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Breast Cancer Research Foundation BCRF-24-132Dr. Miriam and Sheldon G. Adelson Medical Research Foundation 015669-00001NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

The use of antibody-drug conjugates (ADCs) specific to human epidermal growth factor receptor 2 (HER2), such as ado-trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (Enhertu, T-DXd), and trastuzumab duocarmazine (SYD985), to treat breast cancer patients has been associated with a variety of toxicities including corneal epithelial keratitis. The anatomic basis for ocular toxicities has not been established. Using immunohistochemistry, HER2 expression was identified in the human corneal, limbal and conjunctival epithelium of fetal and adult human eyes. We also identified HER2 expression in tissues from the Macaca fascicularis (monkey) to confirm a similar distribution of HER2 expression as found in humans and to support the use of this species as a toxicology model in preclinical testing of anti-HER2 ADCs. As in the human, expression of HER2 in monkey was limited to normal epithelium, as illustrated for the eye, kidney, and uterus. Incubation of normal human corneal epithelial cell lines with trastuzumab or T-DXd demonstrated the capacity for receptor-mediated endocytosis of HER2-targeted therapies by epithelia in the eye. Our findings of HER2 expression in normal human corneal epithelium suggest that the ocular adverse events associated with HER2-targeted ADCs may be driven, at least in part, by an on-target effect.

Indexed as

Erb-b2 Receptor Tyrosine KinasesEyeImmunoconjugatesAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecinCell LineFemaleHumansMacaca fascicularisTrastuzumabAdo-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesTrastuzumabtrastuzumab deruxtecan

Identifiers

PMID42098228
PMCPMC13358114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.